PharmaDrug Enters Letter Of Intent With Licensed Dealer For Pharma Grade Cocaine

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug Inc (CSE: PHRX) is one step closer to commercializing its biosynthetic, pharmaceutical-grade cocaine. The company as of last week has seen its subsidiary, Securedose Synthetics, sign a letter of intent with a Canadian controlled drug substance licensed dealer.

The letter of intent will enable PharmaDrug to begin full GMP-approved manufacturing once it has finalized the process development for its biosynthetic cocaine product. Technology transfer for the provisionally patented synthesis method is set to begin, in advance of a full agreement for the manufacturing and distribution of the product to support safe supply programs globally.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Once details of the formulation and novel manufacturing process are shared with the licensed dealer, it is expected that feedback will be provided on the application of the process in a commercial-scale manufacturing setting. The final manufacturing and distribution agreement is also expected to include marketing initiatives for both research-based demand as well as demand for safe supply programs.

READ: PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

“We are extremely excited to begin the process of partnering with a Canadian controlled drug substance licensed dealer. The partnership will enable us to prepare for the next steps in SecureDose’s forward strategic and tactical plan by preparing us for the production of a commercial batch, with an eye towards distribution opportunities in the regulated supply chain,” commented Robert Steen, CEO of PharmaDrug.

A full agreement is expected to be signed with the undisclosed licensed dealer closer to the finalization of process development and the completion of a test batch.

PharmaDrug last traded at $0.035 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Pharmadrug Completes Super Smart Acquisition, Issues 64.4 Million Free Trading Shares

Pharmadrug Inc (CSE: BUZZ) announced this morning that it has completed its acquisition of Interrobang...

Monday, June 15, 2020, 02:44:06 PM

PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

PharmaDrug Inc (CSE: PHRX) has established a strategic plan to push forward with its intent...
Monday, May 13, 2024, 08:55:00 AM

Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

PharmaDrug's (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine....
Wednesday, March 13, 2024, 08:45:11 AM

PharmaDrug Engages Research Lab To Advance Patented Cocaine Synthesis Method

PharmaDrug (CSE: PHRX) has formally engaged a research lab to refine and advance the development...
Tuesday, April 16, 2024, 09:31:23 AM

PharmaDrug: A Path To Safe Supply

In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company's groundbreaking biosynthetic...
Wednesday, March 13, 2024, 01:30:00 PM